Searchable abstracts of presentations at key conferences in endocrinology

ea0029p143 | Bone & Osteoporosis | ICEECE2012

Glucocorticoid - treatment in the adrogenital syndrome due to deficit of 21-hydroxylase: long-term bone side effects

Camozzi V. , Scaroni C. , De Toni P. , Albiger N. , Zaninotto M. , Mantero F. , Luisetto G.

The purpose of this study was to compare bone mineral density (BMD) and bone metabolism in patients suffering from adrogenital syndrome due to deficit of 21-hydroxylase with those of a group of healthy subjects. A longitudinal follow-up was also carried out in a subgroup of patients.Thirty-eight patients 19-47 years old were compared with a group of healthy, age- and sex-matched controls. Sodium, potassium, calcium, phosphorus, parathyroid hormone (PTH),...

ea0029p52 | Adrenal cortex | ICEECE2012

Efficacy of long-term treatment with retinoic acid in patients with Cushing’s disease

Giraldi F. Pecori , Ambrogio A. , Andrioli M. , Sanguin F. , Karamouzis I. , Corsello S. , Scaroni C. , Arvat E. , Pontecorvi A. , Cavagnini F.

Cushing’s disease, i.e. cortisol excess due to an ACTH-secreting pituitary adenoma, is a rare disorder with considerable morbidity and mortality. Current therapeutic strategies include pituitary surgery, radiation, adrenalectomy and medical treatment with steroidogenesis inhibitors, as drugs aimed at the pituitary adenoma are as yet under investigation. Experimental data showed that retinoic acid restrains ACTH secretion by tumoral corticotrophes thus we decided to evalua...

ea0029p1343 | Pituitary Basic | ICEECE2012

Aryl hydrocarbon receptor interacting protein in somatotroph adenomas: a molecular target for somatostatin analogues?

Jaffrain-Rea M. , Angelini M. , Occhi G. , Turchi A. , Castermans E. , Ceccato F. , Arcella A. , Esposito V. , Giangaspero F. , Pennelli G. , Daly A. , Alesse E. , Scaroni C. , Beckers A.

The aryl hydrocarbon receptor interacting protein (AIP) gene is abundantly expressed in normal somatotrophs. Somatotropinomas in patients with germline AIP mutations (AIPmut) are typically more aggressive than non-AIPmut adenomas and associated with higher GH/IGF1 secretion. AIP downregulation may also occur in sporadic somatotropinomas, especially in invasive tumours. We wished to evaluate the impact of somatostatin analogues (SSA) pre-treatment on AIP expression in sporadic ...